Bioavailability and bioequivalence of etonogestrel from two oral formulations of desogestrel: Cerazette® and Liseta®

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 24, Issue 4, 1999, Pages 335-343

  Timmer, C J ^a,c   Srivastava, N ^b   Dieben, Th O M ^a   Cohen, A F ^b  

^a NV ORGANON   (Netherlands)

^b CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^c Dept of Drug Metab and Kinetics ^*  (Netherlands)

Author keywords

Bioavailability; Cerazette ; Desogestrel; Etonogestrel; Liseta

Indexed keywords

DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; ESTRADIOL; ETONOGESTREL; GESTAGEN;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN EXPERIMENT; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL;

EID: 0033505921     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190042     Document Type: Article

References (31)

1. Viinikka L., Ylikorkala O., Vihko R., Wijnand H.P., Booy M., van der Veen F. (1979) : Metabolism of a new synthetic progestagen, Org 2969, in female volunteers. Investigations into the pharmacokinetics after an oral dose. Eur. J. Clin. Pharmacol., 115, 349-355.
2. Viinikka L., Ylikorkala O., Vihko R., Hasenack H.G., Nieuwenhuyse H. (1980) : Metabolism of a new synthetic progestagen, Org 2969, in female volunteers. The distribution and excretion of radioactivity after an oral dose of the labelled drug. Acta Endocrinol., 93, 375-379.
3. Viinikka L. (1979) : Metabolism of a new synthetic progestagen, Org 2969, by human liver in vitro. J. Steroid Biochem., 10, 353-357.
4. Bergink E.W., Hamburger A.D., de Jager E., van der Vies J. (1981) : Binding of a contraceptive progestagen Org 2969 and its metabolites to receptor proteins and human sex hormone-binding globulin. J. Steroid Biochem., 14, 175-183.
5. Bjarnadóttir R.I., Geirsson R.T., Gottfredsdóttir H. (1997) : An open, non-randomised comparative study on the effects of desogestrel 0.075 mg/day vs. an IUCD on lactation. Acta Obstet. Gynecol. Scand., 76 (Suppl. 167 Pt 4), 53.
6. Collaborative Study Group on the Desogestrel-containing Progestogen-only Pill. (1998) : A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only-pills containing desogestrel 75 μg/day or levonorgestrel 30 μg/day. Eur. J. Contracept. Reprod. Health Care, 3, 169-178.
7. Rice C.F., Killick S.R., Dieben T., Coelingh Bennink H. (1998) : A comparison of the inhibition of ovulation achieved by desogestrel 75 μg daily. Hum. Reprod., 14, 82-85.
8. Rice C.F., Killick S., Hickling D., Coelingh Bennink H. (1996) : Ovarian activity and vaginal bleeding patterns with a desogestrel-only preparation at three different doses. Hum. Reprod., 11, 737-740.
9. Winkler, U.H., Howie H., Bühler K., Korver T., Geurts T.B.P. (1998) : A randomized controlled double-blind study of the effects on hemostasis of two progestogen-only pills containing 75 μg desogestrel or 30 μg levonorgestrel. Contraception, 57, 385-392.
10. Byrjalsen I., Thormann L., Meinecke B., Riis B.J., Christiansen C. (1991) : Sequential estrogen and progestogen therapy: assessment of progestational effects on the postmenopausal endometrium. Obstet. Gynecol., 79, 523-528.
11. Byrjalsen I., Haarbo J., Christiansen C. (1993) : Role of cigarette smoking on the postmenopausal endometrium during sequential estrogen and progestogen therapy. Obstet. Gynecol., 81, 1016-1021.
12. Haarbo J., Hassager C., Jensen S.B., Riis B.J., Christiansen C. (1991) : Serum lipids, lipoproteins, and apolipoproteins during postmenopausal estrogen replacement therapy combined with either 19-nortestosterone derivatives or 17-hydroxyprogesterone derivatives. Am. J. Med., 90, 584-589.
13. Haarbo J., Christiansen C. (1992) : Treatment-induced cyclic variations in serum lipids, lipoproteins, and apolipoproteins after 2 years of combined hormone replacement therapy. Obstet. Gynecol., 80, 639-644.
14. Hassager C., Colwell A., Assiri A.M.A., Eastell R., Russel R.G.G., Christiansen C. (1992) : Effect of menopause and hormone replacement therapy on urinary excretion of pyridinium cross-links: a longitudinal and cross-sectional study. Clin. Endocrinol., 37, 45-50.
15. Marslew U., Riis B., Christiansen C. (1991) : Progestogens: therapeutic and adverse effects in early post-menopausal women. Maturitas, 13, 7-16.
16. Marslew U., Riis B., Christiansen C. (1991) : Desogestrel in hormone replacement therapy: long-term effects on bone, calcium and lipid metabolism, climateric symptoms, and bleeding. Eur. J. Clin. Invest., 21, 601-607.
17. Marslew U., Munk-Nielsen N., Nilas L., Riis B.J., Christiansen C. (1994) : Bleeding pattern and climacteric symptoms during different sequential combined HRT regimens in current use. Maturitas, 19, 225-237.
18. Saure A., Hirvonen E., Tikkanen M.J., Viinikka L., Ylikorkala O. (1993) : A novel oestradiol-desogestrel preparation for hormone replacement therapy: effects on hormones, lipids, bone, climacteric symptoms and endometrium. Maturitas, 16, 1-12.
19. Schlemmer A., Hassager C., Delmas P.D., Christiansen C. (1994) : Urinary excretion of pyridinium cross-links in healthy women; the long-term effects of menopause and oestrogen/progesterone therapy. Clin. Endocrinol., 40, 777-782.
20. Ylikorkala O., Hirvonen E., Saure A., Viinikka L. (1990) : Urinary excretion of prostcyclin and thromboxane metabolites in climacteric women: effect of estrogenprogestin replacement therapy. Prostaglandins, 39, 33-37.
21. Hasenack H.J, Bosch A.M.G., Käär K. (1986) : Serum levels of 3-keto-desogestrel after oral administration of desogestrel and 3-keto-desogestrel. Contraception, 33, 591-596.
22. Back D.J., Grimmer S.F.M., Shenoy N., Orme M.L.E. (1987) : Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel. Contraception, 35, 619-626.
23. Hammond G.L., Bocchinfuso W.P., Orava M., Smith C.L., van den Ende A., van Enk A. (1994) : Serum distribution of two contraceptive progestins: 3-keto-desogestrel and gestodene. Contraception, 50, 301-318.
24. Bergink W., Assendorp R., Kloosterboer L., van Lier W., Voortman G., Qvist I. (1990) : Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulin Am. J. Obstet. Gynecol., 163, 2132-2137
25. Timmer C.J, Apter D., Voortman G. (1990) : Pharmacokinetics of 3-keto-desogestrel and ethinylestradiol released from different types of contraceptive vaginal rings. Contraception, 42, 629-642.
26. Archer D.F., Timmer C.J., Lammers P. (1994) : Pharmacokinetics of a triphasic oral contraceptive containing desogestrel and ethinyl estradiol. Fertil. Steril., 61, 645-651.
27. Steinijans V.W, Diletti E. (1983) : Statistical analysis of bioavailability studies. Eur. J. Clin. Pharmacol., 24, 127-136.
28. Chen M.L. (1992) : Guidance statistical procedures for bioequivalence studies using a standard two-treatment crossover design. Division of Bioequivalence, Office of Generic Drugs (OGD) of the Food and Drug Administration, informal communication 21 CFR 10.90 (b) (9).
29. International harmonization and consensus DIA meeting on bioavailability and bioequivalence testing, requirements and standards (1991). Drug Inform J, 25, 471-480.
30. Midha K.K., Ormsby E.D., Hubbard J.W. et al. (1993) : Logarithmic transformation in bioequivalence: application with two formulations of perphenazine. J. Pharm. Sci, 82, 138-144.
31. Hauschke D., Steinijans V.W., Diletti E. (1990) : A distribution-free procedure for the statistical analysis of bioequivalence studies. Int. J. Pharmacol. Ther. Toxicol., 28, 72-78.